We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Deoxyribozyme Strategy Applied to Infectious Pathogen Detection

By LabMedica International staff writers
Posted on 14 Mar 2013
Print article
A novel strategy has integrated two emerging technologies for point-of-care (POC) analysis of infectious disease targets.

The combination of colorimetric coupling of surface plasmons of gold nanoparticles with deoxyribozymes (DNAzyme) signal amplification technology creates a fast and simple detection method for genetic targets with a simple colorimetric readout.

Scientists at the University of Toronto (ON, Canada) have generated a rapid-diagnostic biosensor that will allow technicians to test for multiple diseases at one time with one small sample, and with high accuracy and sensitivity. The biosensor relies upon gold particles in much the same vein as the average pregnancy test. With a pregnancy test, gold particles turn the test window red because the particles are linked with an antigen that detects a certain hormone in the urine of a pregnant woman.

The scientists can target a particular disease by linking gold particles with DNA strands. When a sample containing the disease gene, such as malaria, is present, it clumps the gold nanoparticles (GNP), turning the sample blue. Rather than clumping the particles together, the team immerses the gold particles in a DNA-based enzyme solution (DNAzyme) that, when the disease gene is introduced, snips the DNA from the gold particles, turning the sample red. The linker strand includes a substrate sequence that can be cleaved by a multicomponent nucleic acid enzyme (MNAzyme), which is one of the reported DNA responsive DNAzymes.

The advantage of this method is that far less of the gene needs to be present for the solution to show noticeable color changes, amplifying detection. A single DNAzyme can snip up to 600 “links” between the target genes. Just a single drop from a biological sample such as saliva or blood can potentially be tested in parallel, so that multiple diseases can be tested in one sitting. The team has also demonstrated that they can transform the testing solution into a powder, making it light and far easier to ship than solutions, which degrade over time. Powder can be stored for years at a time, and offers hope that the technology can be developed into efficient, cheap, over-the-counter tests for diseases such as Human immunodeficiency virus (HIV) and malaria for developing countries, where access to portable diagnostics is a necessity

Warren Chan, PhD, the senior author of the study, who holds a Canada Research Chair in Nanobiotechnology, said, "There's been a lot of emphasis in developing simple diagnostics. The question is how do you make it simple enough, portable enough? Gold is the best medium, because it's easy to see. It emits a very intense color." The authors concluded the MNAzyme-GNP assay provides a simple and fast colorimetric method for detection of genetic targets of bacterial, viral, and parasitic origins with 50 pM sensitivity without the need for purification and separation steps. The study was published online on February 10, 2013, in the journal Angewandte Chemie International Edition.

Related Links:
University of Toronto


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.